| Id |
Subject |
Object |
Predicate |
Lexical cue |
| T35 |
0-168 |
Sentence |
denotes |
Management of moderate to severe HS is challenging as no single drug is universally effective, thus requiring a personalized, patient‐by‐patient approach in most cases. |
| T36 |
169-281 |
Sentence |
denotes |
We reported an uncommon association of HS and SLE treated with secukinumab therapy during the COVID‐19 pandemic. |
| T37 |
282-394 |
Sentence |
denotes |
Previous publications reported clinical improvements obtained by IL‐17A inhibition in treating either HS or SLE. |
| T38 |
395-606 |
Sentence |
denotes |
2 , 3 Secukinumab was successfully tested in an open‐label trial at two different doses that showed the majority of HS patients achieving HiSCR, suggesting that secukinumab could be as effective as adalimumab. |
| T39 |
607-937 |
Sentence |
denotes |
3 Successful treatment of refractory lupus nephritis with secukinumab in a patient complicated with psoriasis vulgaris was described, highlighting that clinical benefits were associated with reduction of activated T helper 17 cells in peripheral blood and reduced infiltration of IL‐17‐positive lymphocytes in renal interstitium. |
| T40 |
938-1034 |
Sentence |
denotes |
4 Thus, we considered secukinumab as a treatment option that resulted effective in treating HS. |
| T41 |
1035-1367 |
Sentence |
denotes |
Notwithstanding the overall effectiveness on HS and no detrimental effects on SLE, secukinumab was interrupted when SARS‐Cov‐2 was diagnosed in accordance with established psoriasis treatment guidelines and the latest recommendations issued by national and international scientific societies on the management of COVID‐19 infection. |
| T42 |
1368-1531 |
Sentence |
denotes |
Notably, our case developed SARS‐Cov‐2 infection during hydroxychloroquine therapy, which is under evaluation for the current management of the COVID‐19 infection. |
| T43 |
1532-1533 |
Sentence |
denotes |
5 |
